Iaso Bio Launches Global R&D Center in Shanghai’s Waigaoqiao and Hosts Forum on 'Opportunities and Challenges of Globalizing China’s Cell Therapy'

May 20, 2025 21:30 CST Updated 21:30

IASO Biotechnology

Cancer Treatment New Drug Developer

On May 20, 2025, IASO Bio's Global Research and Development Center in the Shanghai Waigaoqiao Bonded Area was officially inaugurated. The industry forum titled "Opportunities and Challenges of China's Cell Therapy Globalization," hosted during the same period, concluded successfully. This event invited...Deputy District Governor of Pudong New Area, Xu Lai, and other government leaders, industry experts and partners from Russia, Mexico, Japan, Indonesia, and other countries, as well as colleagues from China's biopharmaceutical field, gathered with over a hundred guests to discuss cutting-edge technologies in the international cell therapy sector and explore the path for the globalization of China’s cell therapy development.

Shanghai Waigaoqiao Bonded Area is known as "The Place Closest to the World"Known as the first batch of pilot areas in China that allow foreign investment to carry out stem cell and gene therapy technology research and development as well as product production, providing comprehensive policy support for the cell and gene industry, including bonded R&D, bonded production, customs facilitation, clinical trials, and more."IASO Bio Global R&D Center, with a construction area of approximately 30,000 square meters, will leverage the unique policy advantages of the Waigaoqiao Bonded Area to establish cutting-edge cell and gene therapy technologies.In the future, the center will strengthen the synergy with the headquarters of Nanjing IASO Biotherapeutics Co., Ltd., extend its reach to the global market, and accelerate the in-depth development of international business.

Mr. Yu Yong

Chairman of Waigaoqiao Group

Today, the soon-to-be-launched global R&D center is not only a strategic fulcrum for IASO Bio to enhance its global competitiveness, but also an important practice for the Free Trade Zone Bonded Area to contribute to Pudong's efforts in building a world-class biopharmaceutical industry cluster.

Professor Qi Lu Gui

Blood Diseases Hospital, Chinese Academy of Medical Sciences

Chief Clinical Expert, Institute of Hematology, Chinese Academy of Medical Sciences

Fokosu^®Has successfully participated in three international multicenter studies, demonstrating the strength and responsibility of Chinese pharmaceutical companies. IASO Bio is driving the progress of Fokos.^®The registration clinical study for second/third-line indications is very courageous. It also demonstrates their confidence, and I myself am very confident that this product will get better and better.

Mr. Zheng Weining

Founder of Shenzhen Canyou Group

Our collaboration with IASO Bio aims to help more disabled individuals and patients overcome physical limitations and regain their ability to work through CGT technology. Looking ahead, we anticipate creating more job opportunities suitable for disabled individuals together with IASO Bio, achieving a harmonious resonance between industry development and social integration.

Ms. Zhang Jinhua

Founder, Chairman and Chief Executive Officer of IASO Bio

Thank you to the Pudong New Area, the Bonded Area Administration, and the Waigaoqiao Group for providing IASO Bio with a three-dimensional support system of 'spatial empowerment + capital assistance + service enhancement.' This innovative ecosystem offers strong developmental support for IASO Bio's Global Research and Development Center, which will help accelerate our innovation.

Thank you to clinical experts, partners, investors, and industry colleagues from China and abroad for your presence and support. With the Waigaoqiao Bonded Area as our strategic fulcrum, we will fully promote the development of China's cell therapy field and global cooperation.

IASO Bio will continue to push the boundaries of life science with an indomitable spirit of innovation and strong independent R&D capabilities. Staying true to its original mission, it is committed to bringing the hope of a cure to patients worldwide.

At the launch ceremony, the attending guests jointly lit the button symbolizing innovation and hope, witnessing IASO Bio ushering in a new chapter of global development.

At the event, IASO Bio reached important strategic cooperation with partners from Japan, Mexico, Russia, Indonesia, and other countries, as well as with Shenzhen Canfriend Group. The cooperation will focus on advancing two key directions:On the one hand, accelerate the registration and commercialization of CAR-T products in overseas markets, and on the other hand, introduce advanced international stem cell therapy technologies and products to expand treatment areas and benefit more patients worldwide.

In the roundtable forum session on "Opportunities and Challenges for China's Cell Therapy Globalization," renowned experts and scholars from China and abroad discussed 1)Global Collaboration —— Expanding Patient Accessibility(From the perspective of international registration processes and patient payment capabilities); 2)Global Innovation——Next-Generation CGT Therapies Technology(In-depth discussion unfolded on two major topics: the challenges in CGT product R&D and manufacturing, and the progress of next-generation CGT in treating cancer, genetic disorders, and chronic diseases.) Experts and scholars from Europe, Asia, and the Americas shared practical experiences from different regions, providing valuable insights for the development of China’s cell therapy industry through diverse perspectives and in-depth exchanges.

Panel Discussion with Industry Experts from China and Abroad

About IASO Bio

IASO Bio, established in 2017, is a leading biopharmaceutical company focused on the research, production, and commercialization of innovative cell therapies. The company builds its innovation foundation on the development of hematological tumor cell-based drugs and expands into autoimmune diseases and antibody-based therapeutics, with comprehensive capabilities spanning early drug discovery, clinical development, regulatory submission, and commercialization. IASO Bio currently has over 10 innovative drug candidates at various stages of development, including the world’s first fully human CAR-T product, an anti-BCMA injectable therapy called Equecabtagene Autoleucel (brand name: Focasux).^®) was approved for marketing by the China National Medical Products Administration (NMPA) in June 2023, for the treatment of adult patients with relapsed or refractory multiple myeloma (R/RMM) who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent). Its frontline indication for the treatment of 2-3 line multiple myeloma (MM) has entered Phase III clinical trials. In addition, Ixazomib Injection has received multiple Investigational New Drug (IND) application approvals in China and the United States for autoimmune diseases.

Simultaneously, the dual-target (CD19/CD22) product CT120 for lymphoma is about to enter Phase II clinical trials. Another product, IASO118, which targets GPRC5D for the treatment of relapsed and refractory multiple myeloma, has received IND approval in China. In addition to cell therapy products, the company’s fully human anti-CD19 antibody product, IASO-782, has obtained IND approval in both China and the United States for the treatment of various autoimmune diseases, with further exploration ongoing for additional autoimmune disease indications. The company has successively reached global business development licensing or research collaborations with overseas cell therapy companies such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, actively exploring the development of next-generation cell therapy products. Relying on its strong management team, innovative product pipeline, in-house GMP manufacturing, and advanced clinical development capabilities, IASO Bio is fully committed to bringing transformative, accessible innovative therapies and the hope of a cure to patients in China and around the world. For more information, please visit the company's official website: www.iasobio.com or LinkedIn page: www.linkedin.com/company/iasobiotherapeutics.